

China Biologic Products, Inc.
Form 8-K
June 20, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): June 20, 2012

CHINA BIOLOGIC PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware

*(State or other jurisdiction of
incorporation or organization)*

001-34566

(Commission File No.)

75-2308816

(IRS Employer ID No.)

**18th Floor, Jialong International Building
19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People's Republic of China**

(Address of Principal Executive Offices)

86 10 6598 3111

Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On June 20, 2012, the board of directors (the “**Board**”) of China Biologic Products, Inc. (the “**Company**”) nominated Mr. Guangli Pang to succeed Mr. Tung Lam as the Chief Executive Officer of Shandong Taibang Biological Products Co. Ltd. (“**Shandong Taibang**”), our majority owned operating subsidiary. Mr. Pang has been the Deputy Chief Executive Officer of Shandong Taibang since its inception and has extensive experience in the pharmaceutical industry in China. The Board has also removed Mr. Lam from any other positions he currently holds at the Company and its subsidiaries. These management changes are expected to be finalized upon the completion of necessary administrative procedures under PRC laws and the constitutional documents of each relevant subsidiary.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 20, 2012

CHINA BIOLOGIC PRODUCTS, INC.

By: /s/David (Xiaoying) Gao

David (Xiaoying) Gao

Chief Executive Officer
